UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

DOP73 Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i150-i151

2023

Volltextzugriff (PDF)

P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1308-i1308

2024

Volltextzugriff (PDF)

P820 Targeting MM-SES-CD < 22.5 for endoscopic improvement is feasible in a clinical trial of Crohn’s disease: A post-hoc analysis of SEAVUE

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1526-i1526

2024

Volltextzugriff (PDF)

P409 Optimal endoscopic healing thresholds defined by MM-SES-CD < 22.5 and SES-CD < 4 are associated with low risk of disease progression in Crohn’s disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i847-i848

2024

Volltextzugriff (PDF)

P548 Vedolizumab clinical decision support tool predicts hospitalisation, surgery, and healthcare resource utilisation

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S388-S388

2019

Volltextzugriff (PDF)

DOP76 Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studies

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i214-i215

2024

Volltextzugriff (PDF)

P545 Long-term efficacy of ozanimod up to 3 years in patient response subgroups identified using group-based trajectory modelling

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1074-i1075

2024

Volltextzugriff (PDF)

DOP78 Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i217-i218

2024

Volltextzugriff (PDF)

PCR158 Assessing the Cost of Work Productivity Loss in a Privately Insured US Population With Inflammatory Bowel Diseases

Value in health, 2024-06, Vol.27 (6), p.S325-S326

2024

Volltextzugriff (PDF)

EE406 Economic Impact of Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease and Ulcerative Colitis: Induction and Maintenance Phase 3 Results on Work Productivity Loss

Value in health, 2024-06, Vol.27 (6), p.S131-S132

2024

Volltextzugriff (PDF)

A167 CATEGORIZING ENDOSCOPIC SEVERITY OF CROHN’S DISEASE USING THE MODIFIED MULTIPLIER SES-CD (MM-SES-CD)

Journal of the Canadian Association of Gastroenterology, 2022-02, Vol.5 (Supplement_1), p.45-47

2022

Volltextzugriff (PDF)

P485 Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S354-S355

2019

Volltextzugriff (PDF)

P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S316-S316

2019

Volltextzugriff (PDF)

P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S433-S433

2019

Volltextzugriff (PDF)

DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysis

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S066-S066

2018

Volltextzugriff (PDF)

DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S036-S036

2018

Volltextzugriff (PDF)

DOP053 Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S067-S068

2018

Volltextzugriff (PDF)

OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S018-S018

2018

Volltextzugriff (PDF)

OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S019-S019

2018

Volltextzugriff (PDF)

DOP006 A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S034-S034

2018

Volltextzugriff (PDF)

Risk of Mortality by Fibrosis Stage in NAFLD: A Systematic Review and Meta-Analysis

HEPATOLOGY, 2016, Vol.64, p.552A

2016

Volltextzugriff (PDF)

S858 Corticosteroid-Sparing Effect in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab Maintenance Therapy

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S635-S635

2023

Volltextzugriff (PDF)

Safety and Effectiveness of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis

Journal of clinical gastroenterology, 2024-04, Vol.58 (4), p.378-388

2024

Volltextzugriff (PDF)

Mo1845 LONG-DURATION DISEASE ASSOCIATED WITH INCREASED TIME TO CLINICAL REMISSION FOLLOWING BIOLOGIC INITIATION IN BIOLOGIC-NAIVE PATIENTS WITH ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1140-S-1140

2024

Volltextzugriff (PDF)

Sa1784 CHARACTERIZING PRACTICE PATTERNS IN DISEASE ACTIVITY MONITORING OF INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING BIOLOGIC INITIATION WITHIN A LARGE REGIONAL HEALTHCARE SYSTEM

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-521-S-522

2024

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(77)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

DOP73 Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)

P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials

P820 Targeting MM-SES-CD < 22.5 for endoscopic improvement is feasible in a clinical trial of Crohn’s disease: A post-hoc analysis of SEAVUE

P409 Optimal endoscopic healing thresholds defined by MM-SES-CD < 22.5 and SES-CD < 4 are associated with low risk of disease progression in Crohn’s disease

P548 Vedolizumab clinical decision support tool predicts hospitalisation, surgery, and healthcare resource utilisation

DOP76 Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studies

P545 Long-term efficacy of ozanimod up to 3 years in patient response subgroups identified using group-based trajectory modelling

DOP78 Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study

PCR158 Assessing the Cost of Work Productivity Loss in a Privately Insured US Population With Inflammatory Bowel Diseases

EE406 Economic Impact of Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease and Ulcerative Colitis: Induction and Maintenance Phase 3 Results on Work Productivity Loss

A167 CATEGORIZING ENDOSCOPIC SEVERITY OF CROHN’S DISEASE USING THE MODIFIED MULTIPLIER SES-CD (MM-SES-CD)

P485 Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy

P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease

P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis

DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysis

DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis

DOP053 Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis

OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis

OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis

DOP006 A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease

Risk of Mortality by Fibrosis Stage in NAFLD: A Systematic Review and Meta-Analysis

S858 Corticosteroid-Sparing Effect in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab Maintenance Therapy

Safety and Effectiveness of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis

Mo1845 LONG-DURATION DISEASE ASSOCIATED WITH INCREASED TIME TO CLINICAL REMISSION FOLLOWING BIOLOGIC INITIATION IN BIOLOGIC-NAIVE PATIENTS WITH ULCERATIVE COLITIS

Sa1784 CHARACTERIZING PRACTICE PATTERNS IN DISEASE ACTIVITY MONITORING OF INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING BIOLOGIC INITIATION WITHIN A LARGE REGIONAL HEALTHCARE SYSTEM

Aktive Filter

Suchergebnisse filtern